TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

December 3, 2018

Study Completion Date

August 14, 2021

Conditions
Squamous Cell Lung Carcinoma
Interventions
DRUG

TAS-102

"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"

Trial Locations (1)

32608

UF Health Cancer Center, Gainesville

All Listed Sponsors
collaborator

Taiho Oncology, Inc.

INDUSTRY

lead

University of Florida

OTHER

NCT02920476 - TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | Biotech Hunter | Biotech Hunter